389 related articles for article (PubMed ID: 22841377)
1. B-cell populations and sub-populations in Sjögren's syndrome.
Hamza N; Bos NA; Kallenberg CG
Presse Med; 2012 Sep; 41(9 Pt 2):e475-83. PubMed ID: 22841377
[TBL] [Abstract][Full Text] [Related]
2. B cells in Sjögren's syndrome: from pathophysiology to diagnosis and treatment.
Cornec D; Devauchelle-Pensec V; Tobón GJ; Pers JO; Jousse-Joulin S; Saraux A
J Autoimmun; 2012 Sep; 39(3):161-7. PubMed ID: 22749831
[TBL] [Abstract][Full Text] [Related]
3. Immune regulation and B-cell depletion therapy in patients with primary Sjögren's syndrome.
Abdulahad WH; Kroese FG; Vissink A; Bootsma H
J Autoimmun; 2012 Aug; 39(1-2):103-11. PubMed ID: 22341852
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD20 antibody in primary Sjögren's syndrome management.
Chen S; Liu Y; Shi G
Curr Pharm Biotechnol; 2014; 15(6):535-41. PubMed ID: 25213362
[TBL] [Abstract][Full Text] [Related]
5. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome.
Lavie F; Miceli-Richard C; Quillard J; Roux S; Leclerc P; Mariette X
J Pathol; 2004 Apr; 202(4):496-502. PubMed ID: 15095277
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiological cytokine network in primary Sjögren's syndrome.
Pers JO; Lahiri A; Tobón GJ; Youinou P
Presse Med; 2012 Sep; 41(9 Pt 2):e467-74. PubMed ID: 22836197
[TBL] [Abstract][Full Text] [Related]
7. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
Cornec D; Costa S; Devauchelle-Pensec V; Jousse-Joulin S; Marcorelles P; Berthelot JM; Chiche L; Hachulla E; Hatron PY; Goeb V; Vittecoq O; Saraux A; Pers JO
J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003
[TBL] [Abstract][Full Text] [Related]
8. Invariant NKT cells are expanded in peripheral blood but are undetectable in salivary glands of patients with primary Sjögren's syndrome.
Guggino G; Ciccia F; Raimondo S; Giardina G; Alessandro R; Dieli F; Sireci G; Triolo G
Clin Exp Rheumatol; 2016; 34(1):25-31. PubMed ID: 26633038
[TBL] [Abstract][Full Text] [Related]
9. B-cell tolerance breakdown in Sjögren's syndrome: focus on BAFF.
Varin MM; Le Pottier L; Youinou P; Saulep D; Mackay F; Pers JO
Autoimmun Rev; 2010 Jul; 9(9):604-8. PubMed ID: 20457281
[TBL] [Abstract][Full Text] [Related]
10. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.
Hamza N; Bootsma H; Yuvaraj S; Spijkervet FK; Haacke EA; Pollard RP; Visser A; Vissink A; Kallenberg CG; Kroese FG; Bos NA
Ann Rheum Dis; 2012 Nov; 71(11):1881-7. PubMed ID: 22615459
[TBL] [Abstract][Full Text] [Related]
11. B cells in Sjögren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue.
Hansen A; Lipsky PE; Dörner T
Arthritis Res Ther; 2007; 9(4):218. PubMed ID: 17697366
[TBL] [Abstract][Full Text] [Related]
12. BAFF overexpression increases lymphocytic infiltration in Sjögren's target tissue, but only inefficiently promotes ectopic B-cell differentiation.
Ding J; Zhang W; Haskett S; Pellerin A; Xu S; Petersen B; Jandreski L; Hamann S; Reynolds TL; Zheng TS; Mingueneau M
Clin Immunol; 2016 Aug; 169():69-79. PubMed ID: 27352977
[TBL] [Abstract][Full Text] [Related]
13. Sjögren's syndrome.
Delaleu N; Jonsson R; Koller MM
Eur J Oral Sci; 2005 Apr; 113(2):101-13. PubMed ID: 15819815
[TBL] [Abstract][Full Text] [Related]
14. B cell-targeted therapies in Sjögren's syndrome.
Tobón GJ; Pers JO; Youinou P; Saraux A
Autoimmun Rev; 2010 Feb; 9(4):224-8. PubMed ID: 19671451
[TBL] [Abstract][Full Text] [Related]
15. [B lymphocytes in Sjögren's syndrome].
Pers JO; Le Pottier L; Devauchelle V; Saraux A; Youinou P
Rev Med Interne; 2008 Dec; 29(12):1000-6. PubMed ID: 18403061
[TBL] [Abstract][Full Text] [Related]
16. [Lymphocyte subsets in labial salivary gland of Sjogren's syndrome].
Li X
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1993 Apr; 15(2):83-8. PubMed ID: 8242827
[TBL] [Abstract][Full Text] [Related]
17. Autoantigen-specific B cells and plasma cells are prominent in areas of fatty infiltration in salivary glands of patients with primary Sjögren's syndrome.
Skarstein K; Jensen JL; Galtung H; Jonsson R; Brokstad K; Aqrawi LA
Autoimmunity; 2019; 52(7-8):242-250. PubMed ID: 31661985
[TBL] [Abstract][Full Text] [Related]
18. Identification of transitional type II B cells in the salivary glands of patients with Sjögren's syndrome.
Daridon C; Pers JO; Devauchelle V; Martins-Carvalho C; Hutin P; Pennec YL; Saraux A; Youinou P
Arthritis Rheum; 2006 Jul; 54(7):2280-8. PubMed ID: 16802367
[TBL] [Abstract][Full Text] [Related]
19. NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment.
Pontarini E; Sciacca E; Grigoriadou S; Rivellese F; Lucchesi D; Fossati-Jimack L; Coleby R; Chowdhury F; Calcaterra F; Tappuni A; Lewis MJ; Fabris M; Quartuccio L; Bella SD; Bowman S; Pitzalis C; Mavilio D; De Vita S; Bombardieri M
Front Immunol; 2021; 12():706737. PubMed ID: 34594326
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive investigation on the distribution of circulating follicular T helper cells and B cell subsets in primary Sjögren's syndrome and systemic lupus erythematosus.
Szabó K; Papp G; Szántó A; Tarr T; Zeher M
Clin Exp Immunol; 2016 Jan; 183(1):76-89. PubMed ID: 26358223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
